| Literature DB >> 35743933 |
Sarolta Borzsák1,2, András Szentiványi1, András Süvegh1, Daniele Mariastefano Fontanini1,2, Milán Vecsey-Nagy1, Péter Banga2,3, Zoltán Szeberin2,3, Péter Sótonyi2,3, Csaba Csobay-Novák1,2.
Abstract
Our purpose was to evaluate the risk associated with the learning curve of starting a complex aortic programme in an Eastern European country. A retrospective study was conducted involving the initial 20 patients (16 males, mean age: 65 ± 11 years) undergoing fenestrated/branched endovascular aortic repair in a single centre. Demographic, anatomical, procedural, and postoperative variables were collected. Our elective patient cohort consisted of 9 pararenal aneurysms (45%) and 11 thoracoabdominal aortic aneurysms (55%), with the latter including 4 chronic dissection cases (20%). A total of 71 branch vessels were incorporated (3.5 ± 0.9 per patient). The per vessel technical success rate was 100%. In-hospital mortality was 5% (1/20). At an average follow-up of 14 ± 22 months, the primary clinical success rate was 45% (9/20) and the secondary clinical success was achieved in 75% of cases (15/20). All-cause mortality at 14 months was 20% (4/20; aortic related: 1/20, 5%). Four bridging stent occlusions were found (5.6%). Mortality and reintervention rates were comparable to the initial results of high-volume centres, while the complexity of our cases and the per vessel technical success rate was comparable to the values reported as late experience. The morbidity of the learning curve could be decreased if operators are skilled in basic endovascular procedures.Entities:
Keywords: aortic aneurysm; branched; endovascular aneurysm repair; fenestrated; stentgraft
Year: 2022 PMID: 35743933 PMCID: PMC9225306 DOI: 10.3390/life12060902
Source DB: PubMed Journal: Life (Basel) ISSN: 2075-1729
Demographics, clinical, and anatomical characteristics.
| Variable | ||
|---|---|---|
| Demographics | Male gender | 16 (80) |
| Mean age, years | 65.5 ± 11.2 | |
| BMI, kg/m2 | 27.3 ± 4.1 | |
| Clinical Characteristics | Hypertension | 16 (80) |
| Smoking | 8 (40) | |
| Hypercholesterolemia | 10 (50) | |
| Diabetes mellitus | 3 (15) | |
| Coronary heart disease | 11 (55) | |
| Chronic obstructive pulmonary disease | 7 (35) | |
| Chronic kidney disease stage III–V | 4 (20) | |
| eGFR, mL/min/1.73 m2 | 74.6 ± 16.9 | |
| Prior aortic repair | 10 (50) | |
| Malignant disease | 5 (25) | |
| ASA status | ASA II | 1 (5) |
| ASA III | 17 (85) | |
| ASA IV | 2 (10) | |
| Anatomical characteristics | Pararenal aortic aneurysm | 9 (45) |
| Thoracoabdominal aortic aneurysm | 11 (55) | |
| Chronic dissection | 4 (20) | |
| Average size of the aortic aneurysm, mm | 72.5 ± 17.0 | |
Abbreviations: n = Number; SD = Standard deviation; BMI = Body mass index; ASA = American Society of Anesthesiologist’s physical status classification.
Procedural details.
| Variable | ||
|---|---|---|
| Device design | Off-the-shelf device | 6 (30) |
| Patient-specific device | 14 (70) | |
| Proximal sealing zone | zone 2–4 | 10 (50) |
| zone 5 | 7 (35) | |
| zone 7 | 1 (5) | |
| zone 8 | 2 (10) | |
| Distal sealing zone | zone 9 | 3 (15) |
| zone 10 | 11 (55) | |
| zone 11 | 6 (30) | |
| Aortic coverage length, mm | 346.6 ± 132.8 | |
| Total incorporated vessels | 71 | |
| Incorporated vessels per patient | Total | 3.6 ± 0.9 |
| 1 vessel | 1 (5) | |
| 2 vessels | 1 (5) | |
| 3 vessels | 5 (25) | |
| 4 vessels | 12 (60) | |
| 5 vessels | 1 (5) | |
| Type of incorporation | Fenestrations | 46 (65) |
| Directional branches | 25 (35) | |
| Procedural data | Contrast volume, ml | 285.4 ± 124.0 |
| Fluoroscopy time, min | 69 ± 39 | |
| Cumulative air kerma, Gy | 3.6 ± 2.5 | |
| ICU length of stay, d | 0.8 ± 1.2 | |
| Total length of stay, d | 5.9 ± 2.4 | |
| Staged repair | 6 (30) | |
| Cerebrospinal fluid drainage | 3 (15) | |
| Temporary aneurysm sac perfusion | 4 (20) | |
| Technical success per vessel | 71 (100) | |
| Primary technical success per patient | 13 (65) | |
Abbreviations: n = Number; SD = Standard deviation; ICU = Intensive care unit.
Figure 1Patient survival (upper) and bridging stent patency (lower) at an average follow-up of 14 ± 22 months.